Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 11/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 2/20 | 0.38 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939201 | 0.92 | CNR2 (0.38) | DHODHTRPM8CNR2USP2 | |
| SCHEMBL11947897 | 0.90 | DYRK1A (0.41) | KDM4CKDM4AKDM5ACNR2EGLN1 | |
| SCHEMBL11947875 | 0.84 | BDKRB1 (0.40) | CNR2USP2 | |
| SCHEMBL940219 | 0.81 | DHODH (0.40) | DHODHTRPM8KDM4CRUNX1KDM4A | |
| SCHEMBL940059 | 0.79 | KDM4A (0.37) | KDM4AKDM5AUSP2 | |
| SCHEMBL11947899 | 0.79 | KDM5B (0.38) | DHODHKDM4CKDM4AKDM5AUSP2 | |
| SCHEMBL938603 | 0.78 | KMT2A (0.41) | TRPM8USP2 | |
| SCHEMBL938977 | 0.76 | C1R (0.36) | KDM4CKDM4AKDM5A | |
| SCHEMBL941264 | 0.76 | KDM4C (0.41) | KDM4CKDM4AKDM5AUSP2 | |
| SCHEMBL940167 | 0.75 | C1R (0.45) | USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440542-B1 | Substituted benzimidazoles, benzonthiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | BDKRB1, BDKRB2, BRD1 | DHODH 3459/4885TRPM8 226/4885KDM4C 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.